Cargando…

Gene Therapy for Lung Diseases

Gene therapy is under development for a variety of lung disease, both those caused by single gene defects, such as cystic fibrosis and α(1)-antitrypsin deficiency, and multifactorial diseases such as cancer, asthma, lung fibrosis, and ARDS. Both viral and nonviral approaches have been explored, the...

Descripción completa

Detalles Bibliográficos
Autores principales: Alton, Eric W.F.W., Davies, Jane C., Geddes, Duncan M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2006
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7121178/
http://dx.doi.org/10.1007/978-1-59259-963-9_28
_version_ 1783515144519680000
author Alton, Eric W.F.W.
Davies, Jane C.
Geddes, Duncan M.
author_facet Alton, Eric W.F.W.
Davies, Jane C.
Geddes, Duncan M.
author_sort Alton, Eric W.F.W.
collection PubMed
description Gene therapy is under development for a variety of lung disease, both those caused by single gene defects, such as cystic fibrosis and α(1)-antitrypsin deficiency, and multifactorial diseases such as cancer, asthma, lung fibrosis, and ARDS. Both viral and nonviral approaches have been explored, the major limitation to the former being the inability to repeatedly administer, which renders this approach perhaps more applicable to conditions requiring single administration, such as cancer. Progress in development and clinical trials in each of these diseases is reviewed, together with some potential newer approaches for the future.
format Online
Article
Text
id pubmed-7121178
institution National Center for Biotechnology Information
language English
publishDate 2006
record_format MEDLINE/PubMed
spelling pubmed-71211782020-04-06 Gene Therapy for Lung Diseases Alton, Eric W.F.W. Davies, Jane C. Geddes, Duncan M. Principles of Molecular Medicine Article Gene therapy is under development for a variety of lung disease, both those caused by single gene defects, such as cystic fibrosis and α(1)-antitrypsin deficiency, and multifactorial diseases such as cancer, asthma, lung fibrosis, and ARDS. Both viral and nonviral approaches have been explored, the major limitation to the former being the inability to repeatedly administer, which renders this approach perhaps more applicable to conditions requiring single administration, such as cancer. Progress in development and clinical trials in each of these diseases is reviewed, together with some potential newer approaches for the future. 2006 /pmc/articles/PMC7121178/ http://dx.doi.org/10.1007/978-1-59259-963-9_28 Text en © Humana Press Inc. 2006 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Article
Alton, Eric W.F.W.
Davies, Jane C.
Geddes, Duncan M.
Gene Therapy for Lung Diseases
title Gene Therapy for Lung Diseases
title_full Gene Therapy for Lung Diseases
title_fullStr Gene Therapy for Lung Diseases
title_full_unstemmed Gene Therapy for Lung Diseases
title_short Gene Therapy for Lung Diseases
title_sort gene therapy for lung diseases
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7121178/
http://dx.doi.org/10.1007/978-1-59259-963-9_28
work_keys_str_mv AT altonericwfw genetherapyforlungdiseases
AT daviesjanec genetherapyforlungdiseases
AT geddesduncanm genetherapyforlungdiseases